Literature DB >> 11719225

WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.

R E Palmer1, A Kotsianti, B Cadman, T Boyd, W Gerald, D A Haber.   

Abstract

The WT1 tumor suppressor gene encodes a zinc finger transcription factor expressed in differentiating glomerular podocytes. Complete inactivation of WT1 in the mouse leads to failure of mesenchymal induction and renal agenesis, an early developmental phenotype that prevents analysis of subsequent stages in glomerular differentiation [1]. In humans with Denys-Drash Syndrome, a heterozygous germline mutation in WT1 is associated with specific defects in glomeruli and an increased risk for developing Wilms Tumor [2,3]. WT1 target genes implicated in cell cycle regulation and cellular proliferation have been proposed [4], but the link between WT1 function and glomerular differentiation is unexplained. Here, we show that inducible expression of WT1 in rat embryonic kidney cell precursors leads to the induction of endogenous Podocalyxin, the major structural membrane protein of glomerular podocytes, which is implicated in the maintenance of filtration slits. Binding of WT1 to conserved elements within the Podocalyxin gene promoter results in potent transcriptional activation, and the specific expression pattern of Podocalyxin in the developing kidney mirrors that of WT1 itself. These observations support a role for WT1 in the specific activation of a glomerular differentiation program in renal precursors and provide a molecular basis for the glomerulonephropathy that is characteristic of Denys-Drash Syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719225     DOI: 10.1016/s0960-9822(01)00560-7

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  44 in total

1.  The Presence and Location of Podocytes in Glomeruli as Affected by Diabetes Mellitus.

Authors:  Kathryn E Maraszek; Briana A Santo; Rabi Yacoub; John E Tomaszewski; Imtiaz Mohammad; Amber M Worral; Pinaki Sarder
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2020-03-16

2.  Genome-Wide Analysis of Wilms' Tumor 1-Controlled Gene Expression in Podocytes Reveals Key Regulatory Mechanisms.

Authors:  Martin Kann; Sandrine Ettou; Youngsook L Jung; Maximilian O Lenz; Mary E Taglienti; Peter J Park; Bernhard Schermer; Thomas Benzing; Jordan A Kreidberg
Journal:  J Am Soc Nephrol       Date:  2015-01-30       Impact factor: 10.121

Review 3.  From ureteric bud to the first glomeruli: genes, mediators, kidney alterations.

Authors:  Vassilios Fanos; Cristina Loddo; Melania Puddu; Clara Gerosa; Daniela Fanni; Giovanni Ottonello; Gavino Faa
Journal:  Int Urol Nephrol       Date:  2014-09-09       Impact factor: 2.370

4.  A novel missense mutation of Wilms' Tumor 1 causes autosomal dominant FSGS.

Authors:  Gentzon Hall; Rasheed A Gbadegesin; Peter Lavin; Guanghong Wu; Yangfan Liu; Edwin C Oh; Liming Wang; Robert F Spurney; Jason Eckel; Thomas Lindsey; Alison Homstad; Andrew F Malone; Paul J Phelan; Andrey Shaw; David N Howell; Peter J Conlon; Nicholas Katsanis; Michelle P Winn
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

5.  The Wilms' tumor gene Wt1 is required for normal development of the retina.

Authors:  Kay-Dietrich Wagner; Nicole Wagner; Valerie P I Vidal; Gunnar Schley; Dagmar Wilhelm; Andreas Schedl; Christoph Englert; Holger Scholz
Journal:  EMBO J       Date:  2002-03-15       Impact factor: 11.598

6.  Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation.

Authors:  Maike Busch; Heinrich Schwindt; Artur Brandt; Manfred Beier; Nicole Görldt; Paul Romaniuk; Eneda Toska; Stefan Roberts; Hans-Dieter Royer; Brigitte Royer-Pokora
Journal:  Hum Mol Genet       Date:  2014-03-11       Impact factor: 6.150

7.  Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7.

Authors:  Yung-Ho Hsu; Wei-Ling Lin; Yi-Ting Hou; Yeong-Shiau Pu; Chia-Tung Shun; Chi-Ling Chen; Yih-Yiing Wu; Jen-Yau Chen; Tso-Hsiao Chen; Tzuu-Shuh Jou
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

8.  Erythropoietin modulation of podocalyxin and a proposed erythroblast niche.

Authors:  Pradeep Sathyanarayana; Madhu P Menon; Olga Bogacheva; Oleg Bogachev; Knut Niss; William S Kapelle; Estelle Houde; Jing Fang; Don M Wojchowski
Journal:  Blood       Date:  2007-04-02       Impact factor: 22.113

9.  CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.

Authors:  Chi-Ming Li; Connie E Kim; Adam A Margolin; Meirong Guo; Jimmy Zhu; Jacqueline M Mason; Terrence W Hensle; Vundavalli V V S Murty; Paul E Grundy; Eric R Fearon; Vivette D'Agati; Jonathan D Licht; Benjamin Tycko
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.

Authors:  Marianne K-H Kim; Jacqueline M Mason; Chi-Ming Li; Windy Berkofsky-Fessler; Le Jiang; Divaker Choubey; Paul E Grundy; Benjamin Tycko; Jonathan D Licht
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.